John Gordan

John Gordan is a Physician Scientist at the University of California San Francisco, affiliated with the Quantitative Biosciences Institute and the Gastrointestinal Oncology Group. His work bridges clinical practice and laboratory research.

Education:

• BA in Biochemistry from Harvard College (2001)
• PhD in Cancer Biology from University of Pennsylvania (2007)
• MD in Medicine from University of Pennsylvania (2009)
• Residency in Internal Medicine at UC San Francisco (2011)
• Clinical Fellowship in Hematology/Oncology at UC San Francisco (2012)

Dr. Gordan's research focuses on primary liver cancers, including hepatocellular carcinoma, cholangiocarcinoma, and fibrolamellar liver cancer. His lab employs proteomic methods to identify novel therapeutic targets and optimize existing treatments. Key areas include oncogenic kinase signaling, hepatitis virus interactions, and Hippo pathway dysregulation, with emphasis on biomarker discovery and combination therapies.

His recent publications (2022-2025) span hepatology, oncology, and molecular biology, addressing topics such as fusion oncogenes in fibrolamellar cancer, drug resistance mechanisms, and computational analysis of rare cancers. The work integrates clinical trial design with basic science, particularly in kinase signaling and precision therapeutics.

Scientific Awards:

• NCI R37 Merit Award (2022)
• Burroughs Wellcome Fund Career Award for Medical Scientists (2018)
• ASCO Young Investigator Award (2015)
• American Cancer Society Postdoctoral Fellowship (2008)
• Saul Winegrad Award for Outstanding Dissertation (2007)

Dr. Gordan's work informs ASCO clinical guidelines for advanced hepatocellular carcinoma and involves collaborations with multidisciplinary teams. His lab investigates small molecule strategies to target oncogenic pathways and explores hepatitis virus remodeling of signaling networks in liver cancer progression.